Combining baricitinib with narrowband UVB phototherapy led to significant repigmentation and enhanced quality of life in ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $742.35 which represents a slight increase of $16.63 or 2.29% from the prior close of $725.72. The stock opened at $731.27 and ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.